share_log

Diversified Trust Co Purchases 4,834 Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)

Diversified Trust Co Purchases 4,834 Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)

多元化信托公司购买了心血管系统公司(纳斯达克股票代码:CSII)的4,834股股票
Defense World ·  2022/12/26 04:41

Diversified Trust Co grew its position in Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) by 32.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,634 shares of the medical device company's stock after buying an additional 4,834 shares during the period. Diversified Trust Co's holdings in Cardiovascular Systems were worth $272,000 at the end of the most recent quarter.

多元化信托公司最近向美国证券交易委员会提交的13F文件显示,该公司第三季度在心血管系统公司的持仓增加了32.7%。该机构投资者持有这家医疗器械公司19,634股票,在此期间又购买了4,834股票。截至最近一个季度末,多元化信托公司在心血管系统公司持有的股份价值27.2万美元。

Other institutional investors have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in shares of Cardiovascular Systems in the 2nd quarter valued at about $34,000. PNC Financial Services Group Inc. boosted its holdings in shares of Cardiovascular Systems by 32.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,025 shares of the medical device company's stock valued at $68,000 after buying an additional 735 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Cardiovascular Systems by 17.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 6,849 shares of the medical device company's stock valued at $98,000 after buying an additional 1,002 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Cardiovascular Systems by 86.3% in the 1st quarter. Captrust Financial Advisors now owns 4,665 shares of the medical device company's stock valued at $105,000 after buying an additional 2,161 shares in the last quarter. Finally, Group One Trading L.P. boosted its holdings in shares of Cardiovascular Systems by 226.5% in the 1st quarter. Group One Trading L.P. now owns 6,200 shares of the medical device company's stock valued at $140,000 after buying an additional 11,100 shares in the last quarter. 86.61% of the stock is currently owned by institutional investors.

其他机构投资者也调整了对该公司的持股。Point72 Hong Kong Ltd在第二季度购买了心血管系统公司的新股,价值约34,000美元。PNC金融服务集团(PNC Financial Services Group Inc.)在第一季度增持了32.1%的心血管系统股票。PNC金融服务集团(PNC Financial Services Group Inc.)现在持有这家医疗设备公司3,025股股票,价值6.8万美元,该公司在上个季度又购买了735股。美国互惠资本管理有限责任公司在第二季度增持了17.1%的心血管系统股票。美国互惠资本管理有限责任公司现在持有这家医疗设备公司6849股,价值98,000美元,在上个季度又购买了1,002股。CapTrust Financial Advisors在第一季度将其在心血管系统公司的股票持有量增加了86.3%。CapTrust Financial Advisors现在持有这家医疗设备公司4,665股股票,价值10.5万美元,上个季度又购买了2,161股。最后,Group one Trading L.P.在第一季度增持了226.5%的心血管系统股票。Group One Trading L.P.在上个季度又购买了11,100股后,现在持有这家医疗设备公司6,200股股票,价值14万美元。86.61%的股票目前由机构投资者持有。

Get
到达
Cardiovascular Systems
心血管系统
alerts:
警报:

Cardiovascular Systems Stock Performance

心血管系统股票表现

Shares of NASDAQ CSII opened at $13.32 on Monday. The company has a current ratio of 6.22, a quick ratio of 5.20 and a debt-to-equity ratio of 0.08. Cardiovascular Systems, Inc. has a 12 month low of $12.26 and a 12 month high of $23.47. The company has a 50 day simple moving average of $14.08 and a two-hundred day simple moving average of $14.40. The stock has a market cap of $557.87 million, a price-to-earnings ratio of -13.32 and a beta of 0.86.

周一,纳斯达克中证股价开盘报13.32美元。该公司的流动比率为6.22,速动比率为5.20,债务权益比率为0.08。心血管系统公司的股价为12.26美元的12个月低点和23.47美元的12个月高位。该公司的50日简单移动均线切入位在14.08美元,200日简单移动均线切入位在14.40美元。该股市值为5.5787亿美元,市盈率为-13.32倍,贝塔系数为0.86。

Cardiovascular Systems (NASDAQ:CSII – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Cardiovascular Systems had a negative net margin of 16.40% and a negative return on equity of 15.51%. The business had revenue of $59.67 million for the quarter, compared to analyst estimates of $59.33 million. As a group, analysts predict that Cardiovascular Systems, Inc. will post -0.67 earnings per share for the current year.
心血管系统公司(纳斯达克代码:CSII-GET Rating)上一次公布季度收益数据是在11月3日星期四。这家医疗器械公司公布了该季度每股收益(0.27美元),低于普遍预期的(0.24美元)和(0.03美元)。心血管系统公司的净利润率为负16.40%,净资产回报率为负15.51%。该业务本季度营收为5967万美元,而分析师预期为5933万美元。分析师预计,作为一个整体,心血管系统公司本年度的每股收益将为0.67美元。

Analysts Set New Price Targets

分析师设定新的价格目标

A number of research firms have recently weighed in on CSII. Barclays began coverage on shares of Cardiovascular Systems in a report on Wednesday, December 21st. They issued an "equal weight" rating and a $15.00 price target on the stock. StockNews.com began coverage on shares of Cardiovascular Systems in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Finally, Lake Street Capital began coverage on shares of Cardiovascular Systems in a research note on Wednesday, December 14th. They issued a "buy" rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $20.00.

一些研究公司最近加入了对CSII的看法。巴克莱在12月21日星期三的一份报告中开始报道心血管系统的股票。他们给出了“同等权重”的评级和15.00美元的目标价。StockNews.com在10月12日星期三的一份研究报告中开始报道心血管系统的股票。他们对该公司的评级为“持有”。最后,Lake Street Capital在12月14日星期三的一份研究报告中开始报道心血管系统的股票。他们对该公司的评级为“买入”,目标价为25美元。一名分析师对该股的评级为卖出,两名分析师对该股的评级为持有,两名分析师对该公司的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为持有,平均目标价为20.00美元。

Cardiovascular Systems Company Profile

心血管系统公司简介

(Get Rating)

(获取评级)

Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

心血管系统公司是一家医疗技术公司,在美国和国际上开发和销售治疗外周和冠状动脉疾病的解决方案。该公司提供外周动脉疾病产品,包括基于导管的平台,用于治疗膝盖以上和膝盖以下的各种斑块类型,包括钙化斑块,以及解决与手术、导管和药物治疗替代方案相关的各种限制;以及外周支持产品。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Cardiovascular Systems (CSII)
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • Cintas Beats Inflation With Operating Leverage
  • Your Decision to Buy Palantir May Simply Be a Matter of Time
  • 免费获取StockNews.com心血管系统研究报告(CSII)
  • MarketBeat:回顾一周12/19-12/23
  • 这些钢铁制造商理应在2023年观察名单上占有一席之地
  • 通胀降温,标普500指数何去何从
  • Cintas以经营杠杆击败通胀
  • 你买下Palantir的决定可能只是个时间问题

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating).

想看看其他对冲基金持有哪些中证指数吗?访问HoldingsChannel.com获取心血管系统公司(纳斯达克代码:CSII-GET评级)的最新13F申报文件和内幕交易信息。

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

接受《每日心血管系统》新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对心血管系统和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发